2022-12-092022-12-092013-04-05Gül, Ö. Ö . vd. (2013). "Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study". Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 757(1), 31-35.1383-57181879-3592https://doi.org/10.1016/j.mrgentox.2013.04.024https://www.sciencedirect.com/science/article/pii/S1383571813002003http://hdl.handle.net/11452/29781This cross-sectional, observational pilot. study was designed to investigate the frequency of different endpoints of genotoxicity (sister-chromatid exchange, total chromosome aberrations, and micronucleus formation) and cytotoxicity (mitotic index, replication index, and nuclear division index) in the peripheral lymphocytes of patients with type-2 diabetes treated with different oral anti-diabetic agents for 6 months. A total of 104 patients who met the American Diabetes Association criteria for type-2 diabetes were enrolled in the study. Of the 104 patients, 33 were being treated with sitagliptin (100 mg/day), 25 with pioglitazone (30 mg/day), 22 with rosiglitazone (4 mg/day), and 24 with medical nutrition therapy (control group). The results for all the genotoxicity endpoints were significantly different across the four study groups. Post hoc analysis revealed that the genotoxicity observed in the sitagliptin group was significantly higher than that observed in the medical nutrition therapy group, but lower than that occurring in subjects who received thiazolidinediones. All of the three cytotoxicity endpoints were significantly lower in patients treated by oral anti-diabetic agents compared with those who received medical nutrition therapy. However, the three indexes did not differ significantly in the sitagliptin, rosiglitazone, and pioglitazone groups. Taken together, these pilot data indicate that sitagliptin and thiazolidinediones may exert genotoxic and cytotoxic effects in patients with type-2 diabetes. Further investigations are necessary to clarify the possible long-term differences between oral anti-diabetic drugs in terms of genotoxicity and cytotoxicity, and how these can modulate the risk of developing diabetic complications in general and cancer in particular.eninfo:eu-repo/semantics/closedAccessBiotechnology & applied microbiologyGenetics & heredityToxicologyType 2 diabetesSitagliptinRosiglitazonePioglitazoneGenotoxicityCytotoxicityActivated receptor-gammaOxidative stressCancerThiazolidinedionesMetaanalysisDamageGlimepirideAgonistsAgentRiskAgedBlood glucoseChromosome aberrationsCross-sectional studiesDiabetes mellitus, type 2FemaleHumansHypoglycemic agentsMaleMicronuclei, chromosome-defectiveMiddle agedPilot projectsPyrazinesSister chromatid exchangeThiazolidinedionesTriazolesArticle0003259546000062-s2.0-848915413693135757123859957Biotechnology & applied microbiologyGenetics & heredityToxicologyRadioprotective Effect; Hesperidin; DiosminPioglitazoneRosiglitazoneSitagliptin2,4 thiazolidinedione derivativeAntidiabetic agentGlucose blood levelPioglitazonePyrazine derivativeRosiglitazoneSitagliptinTriazole derivativeAdultArticleCellular parametersChromosome aberrationControlled studyCross-sectional studyCytotoxicityFemaleGenotoxicityHumanMajor clinical studyMaleMicronucleusMitosis indexNon insulin dependent diabetes mellitusNuclear division indexObservational studyPeripheral lymphocytePilot studyPriority journalReplication indexSister chromatid exchangeAgedDiabetes Mellitus, Type 2Drug effectGlucose blood levelMiddle agedPathology